In 2021, the guideline was further revised, and the diagnosis of AD included more biomarkers, such as the plasma a β 42/A β 40, P - tau217, P - tau181, and NFL levels and cerebrospinal fluid a β 42/A β 42/A β 40. Here, NEFL is linked to Alzheimer disease.